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Aims: To investigate the effects of exercise in combination with a glucagon-like peptide-1
receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes.
Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were
randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both
groups had three supervised 60-minute training sessions per week including spinning and resistance
training.
Results: Glycated haemoglobin (HbA1c) levels dropped by a mean  standard deviation of
2.0%  1.2% (from 8.2%  1.4%) in the exercise plus liraglutide group vs 0.3%  0.9% (from
8.0%  1.2%) in the exercise plus placebo group (P < .001), and body weight was reduced more
with liraglutide (−3.4  2.9 kg vs −1.6  2.3 kg; P < .001). Compared with baseline, similar
reductions were seen in body fat (exercise plus liraglutide: −2.5%  1.4% [P < .001]; exercise
plus placebo: −2.2%  1.9% [P < .001]) and similar increases were observed in maximum oxygen
uptake (exercise plus liraglutide: 0.5  0.5 L O2/min [P < .001]; exercise plus placebo: 0.4 
0.4 L O2/min [P = .002]). Greater reductions in fasting plasma glucose (−3.4  2.3 mM vs
−0.3  2.6 mM, P < .001) and systolic blood pressure (−5.4  7.4 mm Hg vs −0.6  11.1 mm
Hg, P < .01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups
experienced similar increases in quality of life during the intervention.
Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treat-
ment near-normalized HbA1c levels and caused a robust weight loss when compared with
placebo. These results suggest that a combination of exercise and GLP-1RA treatment is
effective in type 2 diabetes.
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exercise, GLP-1, GLP-1 receptor agonist, glucagon-like peptide-1, liraglutide, randomized
study, type 2 diabetes
1 | INTRODUCTION
Physical activity is one of the three cornerstone recommendations
(along with diet and medication) in the treatment of type 2 diabetes.1–5
Exercise training improves aerobic capacity and muscular strength
and is often associated with fat loss and increased muscle mass. Fur-
thermore, exercise training has a beneﬁcial effect on insulin-mediated
glucose uptake and is associated with increased glucose transporter
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4 (GLUT4) expression and improved insulin signalling in skeletal
muscle.6,7 Despite several studies reporting signiﬁcant reductions in
glycated haemoglobin (HbA1c) of 0.4% to 0.6% after increasing the
level of physical activity, it is often not sufﬁcient to normalize glycaemic
control in patients with type 2 diabetes.2,8,9 Glucagon-like peptide-1
(GLP-1) is an incretin hormone secreted from enteroendocrine L cells
located in the distal jejunum and ileum in response to meal ingestion.
GLP-1 is known mainly for its glucose-lowering and satiety-promoting
effects.10 Since 2006, GLP-1 receptor agonists (GLP-1RAs) have been
used for the treatment of patients with type 2 diabetes.11 Liraglutide is
a once-daily administered GLP-1RA with beneﬁcial effects on HbA1c
levels, body weight and body composition in obese dysregulated
patients with type 2 diabetes.11 Nevertheless, a substantial proportion
of GLP-1RA-treated patients do not reach glycaemic targets.
Exercise and GLP-1RAs have each been used for the treatment
of patients with type 2 diabetes for several years; however, the com-
bination of the two has, to our knowledge, never been evaluated in
prospective trials before. We hypothesized that exercise training
combined with GLP-1RA treatment would result in clinically relevant
improvements in HbA1c and a range of other health-related variables,
in obese, sedentary and dysregulated patients with established type
2 diabetes.
2 | METHODS
2.1 | Study design and endpoints
The study was a 16-week, randomized, double-blind, placebo-
controlled study conducted at the Center for Diabetes Research, Gen-
tofte Hospital, University of Copenhagen, Denmark. The study was
conducted in accordance with the international Conference on Har-
monization Guidelines for Good Clinical Practice and the Declaration
of Helsinki. The study was designed and conducted by the authors,
and the authors vouch for the data and analyses, as well as the ﬁdelity
of this report to the study protocol. The study was an investigator-
initiated study, sponsored by Novo Nordisk, but Novo Nordisk had no
role in the study design, data analysis or reporting of results. The pri-
mary endpoint was change in HbA1c (from baseline until end of study
(16 weeks)). Secondary outcomes included changes in body weight,
body composition, maximum oxygen uptake (VO2max), fasting plasma
glucose (FPG), serum insulin, serum C-peptide, plasma glucagon, plasma
concentrations of incretin hormones, liver enzymes, lipids, blood pres-
sure, heart rate and quality of life (QoL). Further secondary outcomes,
insulin resistance and β-cell function, were evaluated by homeostatic
model assessment (HOMA-IR and HOMA-β, respectively).
Patients were recruited from the Diabetes Outpatient Clinic at
Gentofte Hospital, Denmark, and through advertisement. Oral and
written informed consent were obtained before inclusion. Inclusion
criteria were: age >18 years; type 2 diabetes treated with diet and/or
metformin; HbA1c between 7% and 11% (53-97 mmol/mol), body
mass index (BMI) > 25 kg/m2; and sedentary lifestyle (self-reported
physical activity <150 min/wk). Exclusion criteria were clinically rele-
vant cardiovascular disease, impaired liver function, anaemia and/or
impaired renal function. Eligible patients were randomly assigned to
either exercise training plus liraglutide (exercise plus liraglutide) or to
exercise training plus placebo (exercise plus placebo) for 16 weeks
(Figure 1). An employee otherwise not involved in the study carried
out the randomization at a 1:1 ratio from a prespeciﬁed randomization
list. The exercise training consisted of three 60-minute supervised
training sessions per week (in groups). Twice per week the patients
participated in spinning sessions (Indoor Body Bike Supreme; Pedan,
Køge, Denmark) with an average intensity of 65% to 85% of maximum
heart rate (monitored by RS300X; Polar, Kempele, Finland). The pro-
gramme for spinning sessions was modelled on traditional
spinning programs with music and focusing on cardio-training with
incorporated high-intensity intervals of 30-second sprints (4-10
repetitions) followed by 1 minute of active recovery. The third
session consisted of 8 different resistance exercises (squat, lunges,
biceps, triceps, whole-body [modulated Olympic lift], bench press,
shrugs and plank), and 3 sets of 12 repetitions with 30-second to 45-
second rests between each set in order to recruit the major muscle
groups. Resistance exercise training was performed with barbells (Reebok,
Canton, Massachusetts) with individually adjustable weight loads. Exercise
training compliance was deﬁned as no less than 85% participation. All
exercise sessions were conducted under the supervision of trained exer-
cise physiologists (P.M. and S.N.). The patients were repeatedly instructed
not to change their diet or physical activity during the study period except
for the study intervention. A questionnaire describing the frequency and
composition of the daily food intake before, midway and at the end of the
study was used. The study drugs used were the GLP-1 analogue, liraglu-
tide (Victoza), and placebo, which were supplied by Novo Nordisk in
blinded pens for subcutaneous (s.c.) injections. After baseline evaluation,
the patients received once-daily s.c. injections of 0.1 mL of study medica-
tion (0.6 mg liraglutide or placebo) in the evening for 1 week, 0.2 mL
(1.2 mg liraglutide or placebo) the following week and thereafter 0.3 mL
(1.8 mg liraglutide or placebo) for the remaining study period. Patients
were examined in the fasting state at baseline and at the end of the study
with blood samples, blood pressure, resting heart rate, dual-energy X-ray
absorptiometry scan and physical ﬁtness test. End of study examinations
were performed after the last liraglutide or placebo dose was given, the
evening before and 42 to 75 hours after the last bout of exercise.
2.2 | Experimental procedures
A dual-energy X-ray absorptiometry scan (DPX–IQ Lunar, General Elec-
tric Lunar Corporation, Madison, Wisconsin) was performed to assess
body composition. Fat distribution was evaluated as the relative propor-
tion of fat tissue in the android (abdominal) and the gynoid (hip and
thigh) regions. The physical ﬁtness level of the patients (VO2max) was
estimated from a two-step sub-maximum bicycle test at baseline and at
the end of the intervention. Each patient worked at two different work-
loads on a stationary bicycle ergometer (Monark ergomedic 839 E,
Monark, Vansbro, Sweden). The workload was increased until a heart
rate of 110 to 120 beats/min was achieved. At steady-state heart rate,
oxygen uptake was measured (MasterScreen CPX system; Intramedic,
Gentofte, Denmark). The workload was then increased to achieve a
heart rate of 140 to 160 beats/min and oxygen uptake at steady state
was measured again. The duration of the test was 10 to 12 minutes.
VO2max was estimated from the measurements of VO2 during the two-
MENSBERG ET AL. 173
point step test and an estimation of maximum heart rate.12 Resting
heart rate and blood pressure were measured on the left arm after the
patients had rested for 10 minutes. A health-related questionnaire, the
Short-Form-36 Health Survey, was used to evaluate changes in QoL.13
2.3 | Analytical assessment
A colorimetric assay was used to measure HbA1c (Vitros 5.1 FS;
Ortho-Clinical Diagnostics, Linden, New Jersey). Concentrations
of glucose were measured by the glucose oxidase method, using a
glucose analyser (Yellow Springs Instrument model 2300 STAT plus
analyser; YSI Inc., Yellow Springs, Ohio). Insulin and C-peptide concen-
trations were measured using a two-sided electrochemiluminescence
immunoassay (Siemens Healthcare, Ballerup, Denmark).14,15 Concen-
trations of total GLP-1, glucose-dependent insulinotropic polypeptide
(GIP) and glucagon were measured by radioimmunoassays, as
previously described.16,17 Assessment of triglycerides and lipids was
measured using reﬂectance spectrophotometry (Vitros 5.1, Johnson &
Johnson, Ortho-Clinical Diagnostics, New Brunswick, New Jersey).
2.4 | Calculations and statistical methods
Steady-state insulin resistance (HOMA-IR) and β-cell function
(HOMA-β) were estimated using the HOMA2 calculator.18 The statis-
tical analyses were performed using STATA 12.1 (STATA Corp, LP,
College Station, Texas). Data are reported as mean  standard devia-
tion; in case of non-normal distribution, data were log-transformed
and back-transformed. Estimates are reported as geometric means
with 95% conﬁdence interval (CI). Differences between mean values
in the two groups were analysed using Student’s t-test. Analyses of
between-group differences were performed by analysis of covariance
(ANCOVA) with the end-of-study value as the dependent variable
Screened (n=89) 
Screening failures (n=53) 
Not meeting inclusion criteria (n=41) 
Other reasons (n=12) 
Completed the intervention (n=17) 
Analysed (n=17)
Allocated to liraglutide group (n=18) 
Received allocated intervention (n=17)
Excluded after randomization (too low 
exercise compliance)(n=1) 
Allocated to placebo group (n=16) 
Received allocated intervention (n=16)
Completed the intervention (n=16) 
Analysed (n=16) 
 (n=36) 
Withdrawn, patient’s decision (n=2)
Pre-screened (n=293) 
Enrolment
Allocation
Analysis
Randomly assigned to study drug or placebo
FIGURE 1 Consort ﬂow diagram showing patient numbers at each stage of the study.
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and the baseline value as the independent variable. P values of <.05
were considered to indicate statistical signiﬁcance. The statistical ana-
lyses were performed by P.M. and M.T.J.
2.5 | Study registration
The study was approved by the Danish Medicines Agency (EudraCT num-
ber: 2011-002739-24) and the Scientiﬁc-Ethical Committee of the Capital
Region of Denmark (registration number: H-4-2011-073), notiﬁed to the
Danish Data Protection Agency (reference number 2007-58-0015) and
registered at ClinicalTrials.gov (ID: NCTO1455441). The study conformed
to the latest revision of the Declaration of Helsinki. The study was moni-
tored by the Good Clinical Practice unit of University of Copenhagen
and was conducted in compliance with the protocol and national
guidelines including Clinical Trials Directive 2001/20/EC.
3 | RESULTS
From December 2011 to March 2013, a total of 34 patients were
enrolled in the study, of whom 33 completed the full study. One
patient was excluded because of lack of exercise compliance. Patient
characteristics were similar in the two groups (Table 1). Medical treat-
ment was similar in the groups and remained unchanged during the
study. Besides metformin, patients received no medication known to
interfere with glucose metabolism.
3.1 | Glycated haemoglobin
Patients receiving exercise plus liraglutide experienced pronounced
reductions in HbA1c, whereas no signiﬁcant change was observed in
the exercise plus placebo group (Table 2, Figure 2A). In the exercise
plus liraglutide group, 77% of patients obtained an HbA1c <7%
(53 mmol/mol) and 53% normalized their HbA1c concentration
(<6.0% [42 mmol/mol]). In the exercise plus placebo group, the corre-
sponding values were 25% and 6%, respectively (Figure 2F).
3.2 | Body weight and body composition
The mean (range) body weight was reduced by 3.4 (−8.5 kg to +2.3)
kg in patients treated with exercise plus liraglutide, whereas it
remained unchanged with exercise alone (−1.6 [−9.3 to +2.8] kg;
Figure 2C). A signiﬁcant reduction in body fat (%) was observed in
both groups (Table 2, Figure 2D). Furthermore, gynoid and android
fat (%) decreased signiﬁcantly in both groups, with no difference
between the groups. Lean body mass was unchanged from baseline
in both groups (Table 2). Data from the simple questionnaire inquiring
about the frequency and composition of the daily food intake before,
midway and at the end of the study showed little or no change in
food intake between the groups over 16 weeks.
3.3 | Exercise compliance and physical ﬁtness
Overall exercise compliance was 89%  4%, equal to ~2 hours and
41 min/wk during the 16-week intervention period. During spinning
sessions, the mean intensity was 77%  2% of estimated maximum
heart rate, with no difference between the groups. VO2max increased
signiﬁcantly, by ~17% in both groups, after 16 weeks (Figure 2E).
3.4 | FPG, insulin, C-peptide and HOMA-IR/β
A signiﬁcant effect on FPG was seen with exercise plus liraglutide,
whereas exercise plus placebo had no effect on FPG level (Figure 2B).
No changes were observed in fasting levels of insulin and C-peptide,
respectively, in any of the groups. The estimated HOMA-IR and esti-
mated steady-state β-cell function, HOMA-β, were both signiﬁcantly
improved with exercise plus liraglutide, whereas no changes were
observed with exercise plus placebo (Table 3).
3.5 | Lipids, liver enzyme, glucagon, GLP-1 and GIP
concentrations
Lipids were unchanged after the interventions in both groups
(Tables 2 and 3). Alanine transaminase decreased in both groups,
whereas aspartate transaminase remained unchanged. No changes in
fasting glucagon, GLP-1 or GIP were observed (Table 3).
3.6 | Blood pressure and heart rate
A signiﬁcant reduction in systolic blood pressure was found in the
exercise plus liraglutide group. No changes were seen in diastolic
blood pressure or heart rate (Table 2).
3.7 | Health-related QoL
The health-related QoL summary score was signiﬁcantly improved in
the general health component and the physical function component
in both groups without differences between the groups in any of the
components (data not shown).
TABLE 1 Baseline characteristics of the patients
Exercise plus
liraglutide
Exercise plus
placebo
P
Baseline
(n = 17)
Baseline
(n = 16)
Age, years 56.5  9 55.6  12 .79
Sex: female, n (%) 4 (24) 6 (38) .38
Duration of diabetes,
years
6.0  5.2 3.7  3.3 .20
Diet/metformin, n 0/17 3/13
Daily dose metformin, mg 1374  607 1628  936
FPG, mM 9.9  2.7 10.2  3.1 .91
HbA1c, % 8.2  1.4 8.0  1.2 .58
HbA1c, mmol/mol 66.0  16.0 64.0  13.0
Body weight, kg 101.0  14.5 96.8  17.4 .45
BMI, kg/m2 32.5  3.7 32.4  5.2 .95
VO2max estimated,
L O2/min
2.9  0.9 2.5  0.7 .11
Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglo-
bin; VO2max, maximum oxygen uptake.
Data are presented as mean  standard deviation.
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3.8 | Adverse events
Gastrointestinal side effects (mild/moderate and transient nausea,
vomiting and diarrhoea) were observed in 24% of the patients in the
exercise plus liraglutide group vs 6% in the exercise plus placebo
group. No episodes of hypoglycaemia were reported. No serious
adverse events (including pancreatitis) were seen in the study.
4 | DISCUSSION
We show, for the ﬁrst time, that overweight dysregulated and seden-
tary patients with type 2 diabetes receiving supervised exercise train-
ing in combination with the GLP-1RA liraglutide for 16 weeks
achieved: (1) improved glycaemic control; (2) reduction in body
weight; and (3) decreased systolic blood pressure compared with
patients receiving supervised exercise training combined with pla-
cebo. In both groups, improvements in physical ﬁtness, body fat and
QoL were observed. Lean body mass was unchanged in both groups,
despite weight loss. The overall safety proﬁle of liraglutide was con-
sistent with ﬁndings in previous reports.19,20 Interestingly, no changes
in resting heart rate were detected in any of the groups, which is in
contrast to previous studies with continuously acting GLP-1RAs,
which reported a sustained increase in heart rate of approximately
2 to 4 beats/min.19–21 Thus, further studies are warranted to eluci-
date whether exercise training is able to neutralize the well-known
increase in heart rate seen with this class of glucose-lowering drugs.
An important limitation of the present study is the relatively
small sample size of patients, reducing the power to detect subtle
changes and increasing the risk of type II statistical errors. Despite
this, we were able to demonstrate clinically relevant differences
between the two groups. Another limitation of the study is the
absence of diet records, which could have shown possible changes in
diet after GLP-1RA treatment. Strengths of the study include the vali-
dated methods used; the study was performed as a single-centre, ran-
domized, double-blind, placebo-controlled study, with only few
physicians and experienced exercise physiologists involved (all the
TABLE 2 Changes between baseline and end of study
Exercise plus
liraglutide
Exercise plus
liraglutide
Difference
Exercise plus
placebo
Exercise plus
placebo
Difference
P value
between
groups
Baseline
(n = 17)
End of
study (n = 17)
Baseline
(n = 16)
End of
study (n = 16)
Glucose
HbA1c, % 8.2  1.4 6.2  0.7*** −2.0  1.2 8.0  1.2 7.7  1.5 −0.3  0.9 <.001
HbA1c, mmol/mol 66.0  16.0 44.0  8.0*** −22.0  14.0 64.0  13.0 61.0  17.0 −3.0  10.0 .001
FPG, mM 10.4  3.4 7.0  1.6*** −3.4  2.3 10.0  3.1 9.8  3.7 −0.3  2.6 .010
Incretin hormones and glucagon (fasting levels)
Glucagon, pM 9.6  2.9 9.4  3.2 −0.3  3.2 9.4  3.7 8.2  2.1 −1.2  3.2 .23
GLP-1, pM 18.7  3.9 19.3  5.6 +0.6  6.3 20.1  8.2 18.1  5.7 −2.0  5.4 .30
GIP, pM 13.9  4.0 16.3  5.2 +2.4  7.1 13.1  4.0 17.0  8.5 +4.0  9.3 .82
Body composition
Body weight, kg 101.0  14.5 97.6  14.9*** −3.4  2.9 96.8  17.4 95.2  17.7 −1.6  3.2 .10
Body mass index, kg/m2 32.5  3.7 31.3  3.4*** −1.1  1.1 32.4  5.2 31.8  5.1* −0.5  1.0 .11
Fat percent, % 34.3  6.3 31.8  6.8*** −2.5  1.4 37.0  6.5 34.8  7.0*** −2.2  1.9 .77
Gynoid fat, % 34.4  9.1 32.5  9.6*** −2.0  1.6 38.8  9.2 36.3  8.6*** −2.4  1.9 .53
Android fat, % 44.6  4.5 41.4  5.2*** −3.2  2.3 45.9  6.5 42.8  7.8*** −3.1  3.0 .97
Lean body mass, kg 63.3  12.2 63.4  12.8 0.1  2.2 58.0  12 58.7  12.1 0.7  1.5 .42
Blood pressure and heart rate
SBP, mm Hg 136.2  8.9 130.8  8.8** −5.4  7.4 136.4  11.0 135.8  11.6 −0.6  11.1 .11
DBP, mm Hg 82.1  7.0 81.5  7.2 −0.5  4.5 84.1  7.0 81.8  8.0 −2.3  5.5 .41
Resting heart rate - bpm 69.9  8.9 71.3  9.4 +1.4  7.6 70.1  11.1 68.1  12.7 −2.0  7.7 0.22
VO2max, L/O2/min 2.9  0.9 3.4  1.1*** +0.5  0.5 2.5  0.7 2.9  0.8** +0.4  0.4 .92
Lipid proﬁle
Total cholesterol, mM 4.7  1.1 4.4  1.3 −0.3  0.8 4.2  0.9 4.3  0.9 +0.1  0.9 .44
HDL cholesterol, mM 1.2  0.4 1.2  0.3 −0.02  0.2 1.2  0.3 1.3  0.4 +0.1  0.2 .50
LDL cholesterol, mM 2.6  1.0 2.4  1.2 −0.2  0.8 2.2  0.9 2.3  0.8 +0.1  0.8 .35
VLDL cholesterol, mM 0.8  0.5 0.7  0.4 −0.1  0.4 0.7  0.3 0.7  0.3 −0.07  0.2 .65
Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like
peptide-1; SBP, systolic blood pressure; VO2max, maximum oxygen uptake.
Data are mean  standard deviation
*P < .05, **P < .01 and ***P < .001 compared with baseline value within the group.
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exercise sessions were performed under the supervision of the same
two exercise physiologists). Supervised training was chosen because
previous studies have shown improved results with supervision22 and
to support adherence to exercise training and exercise intensity. The
period of 16 weeks was selected to allow sufﬁcient time for uptitra-
tion of study drug (liraglutide and placebo) so that the maximum
recommended dose could be maintained for a full 3-month period
necessary for optimum evaluation of the primary endpoint (HbA1c)
and, furthermore to ensure slow adaptation to exercise training to
avoid injuries. A GLP-1RA as a glucose-lowering drug was selected
because of the well-documented effect on glycaemic control and
body weight in type 2 diabetes combined with a low risk of hypogly-
caemia.11 Only a limited number of previous trials with liraglutide
have observed reductions in HbA1c up to 1.5% (in the majority of
trials reductions ranged from 0.9% to 1.1%).11 Pratley et al.23 found
HbA1c reduction of 1.5% from baseline HbA1c levels of 8.4% after
26 weeks of treatment. The Liraglutide Effects and Action in Diabe-
tes (LEAD) 4 and 5 studies reported HbA1c decreases of 1.5% and
1.3%, respectively, after 26 weeks of treatment with liraglutide, both
in combination with other glucose-lowering agents (metformin plus
rosiglitazone or glimepiride).24,25 Several possible explanations for the
near-normalization of HbA1c after treatment with exercise plus lira-
glutide in the present study should be considered. At least part of the
improved glycaemic control in patients treated with liraglutide relies on
the well-established glucose-lowering effects of GLP-1: the glucose-
dependent stimulation of insulin secretion and the inhibition of gluca-
gon secretion10 and in the brain, respectively.26 Exercise training is
known to increase insulin sensitivity of skeletal muscle in both healthy
individuals and in patients with type 2 diabetes27,28 and improves
β-cell function in patients with type 2 diabetes with well-preserved
residual β-cell function.10 In individuals with impaired glucose tolerance
and in patients with type 2 diabetes, β-cell function has been shown to
be a better predictor of improvement in glycaemic control than insulin
sensitivity.29 Therefore, the beneﬁcial effect of liraglutide on glycaemic
control in the present exercise training study seems at least in part to
be attributable to the insulinotropic effect of liraglutide, in line with
the marked improvement in HOMA-β (Table 3). Nevertheless, the sub-
stantial improvement in glycaemic control in the exercise plus liraglu-
tide group, which markedly surpasses what previously has been
observed with liraglutide in sedentary patients with type 2 diabetes, is
probably attributable to the combination of improved β-cell function,
as well as increased peripheral insulin sensitivity. In the exercise plus
placebo group we assume that the lack of improvement in glycaemic
control despite an expected increase in muscle insulin sensitivity27,29
may be attributable to inability of the residual β-cell reserve to beneﬁt
from increased insulin sensitivity.
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Type 2 diabetes develops as a consequence of insulin resist-
ance and impaired β-cell function, but it is a very heterogeneous
disease with a multifactorial background (eg, genes, lifestyle, obe-
sity, dyslipidaemia and inﬂammation).30 This might partially explain
why patients with type 2 diabetes, including the patients in the
present study, have heterogeneous responses to glucose-lowering
therapies, such as GLP-1RAs. Exercise beneﬁts most, but not all,
individuals31 and it cannot be ruled out that some of the patients
in the present study might have been non-responders and there-
fore failed to demonstrate exercise-induced metabolic improve-
ments. Inﬂammation in the adipose tissue and dysregulation of
adipokines is closely associated with obesity and type 2 diabetes.
Also, inﬂammation has been shown to induce peripheral insulin
resistance32 as well as β-cell dysfunction.33,34 Several studies have
indicated that both GLP-1 receptor agonists35 and exercise36 have
anti-inﬂammatory effects. The pronounced effect on glycaemic
control during the exercise plus liraglutide group, may to some
extent, be explained by the well-known anti-inﬂammatory effects
of both treatment methods. In larger and longer-lasting interven-
tion studies, the effects on HbA1c might be less pronounced, as
previously found in large-scale studies; for example, the LEAD
4 and 5 studies.24,25,37
In the present study QoL was not further improved with liraglu-
tide plus exercise despite improved glycaemic control compared with
exercise alone. However, QoL was not inferior despite some side
effects resulting from liraglutide treatment. These ﬁndings could indi-
cate that exercise training is an essential factor for improvements in
health-related QoL. Because adequate lifestyle changes are often dif-
ﬁcult to implement and maintain in patients with type 2 diabetes,
exercise in combination with liraglutide treatment may be a way to
amplify motivation for change when the patients experience noticea-
ble results from the effects of both exercise and liraglutide.
In conclusion, the combination of supervised exercise training
and liraglutide induced major improvements in glycaemic control and
may be an attractive treatment option for obese, dysregulated
patients with type 2 diabetes on diet and/or metformin who are able
to perform moderate- to high-intensity exercise training.
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